Alphamab Oncology (HKG:9966)
5.22
-0.11 (-2.07%)
Nov 19, 2026, 11:50 AM HKT
Alphamab Oncology Revenue
Alphamab Oncology had revenue of 271.24M CNY in the half year ending June 30, 2026, with 56.28% growth. This brings the company's total for the last twelve months to 518.03M, down -34.09% year-over-year. In the year 2025, Alphamab Oncology had annual revenue of 566.24M, down -11.54%. That makes Alphamab Oncology the 24,836th largest company in the world by revenue and 1,471st in Hong Kong.
Revenue (ttm)
518.03M CNY
Revenue Growth
-34.09%
P/S Ratio
8.62
Revenue / Employee
1.01M CNY
Employees
515
Market Cap
5.05B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 566.24M | -73.85M | -11.54% |
| Dec 31, 2024 | 640.08M | 421.31M | 192.58% |
| Dec 31, 2023 | 218.77M | 51.93M | 31.12% |
| Dec 31, 2022 | 166.85M | 20.82M | 14.26% |
| Dec 31, 2021 | 146.02M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Shanghai Haohai Biological Technology | 2.64B |
| Frontage Holdings | 2.18B |
| Lepu Biopharma | 1.14B |
| Ocumension Therapeutics | 1.08B |
| Suzhou Ribo Life Science | 536.18M |
| Nanjing Leads Biolabs | 246.16M |
| CARsgen Therapeutics Holdings | 157.72M |